Shanghai Celliver Biotechnology Co., Ltd. announced that it will raise CNY 20,000,000 in an equity funding on December 13, 2023. The transaction will include participation from returning investors, Shanghai Kinetic Medical Co., Ltd for CNY 5,000,000 and its stake will increase from 2.9775% to 3.6158% and Shanghai Heji Management Consulting Partnership Enterprise (L.P.) for CNY 15,000,000 and its stake will increase from 5.4908% to 7.5055%. Upon the closing, the company's registered capital will increase from CNY 7,545,402 to CNY 7,770,638.

The transaction has been approved at the twelfth meeting of the fifth board of directors. The round will be raised at a post-money valuation of CNY 690,000,000.